CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Now revised and updated, explore CADTH’s free online resource for grey literature searching, “Grey Matters: a practical tool for searching health-related grey literature.”
Grey Matters: a practical tool for searching health-related grey literature
In order to use the tool:
save file
open file
“Open as read only?” will appear
...
We are pleased to announce the appointment of Brent Fraser to the position of Vice-President, Pharmaceutical Reviews, effective August 4, 2015. In this role, Brent will be responsible for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, and all other aspects of CADTH work in the pharmaceutical space. Brent joins CADTH from t...
The 2017 CADTH Symposium will feature another outstanding roster of Canadian and international experts, thought-provoking plenary sessions, educational workshops, and insightful panel, oral, and poster presentations. We’re coming back to Ottawa so you can also enjoy the history and pageantry of the year-long celebration of Canada’s 150th anniv...
EVIDENCE FOR EVERYONE Expanding the Reach of Health Technology Assessment Initially established as a tool for policy-makers, health technology assessment (HTA) now supports a much broader range of decision-makers. Everyone — whether technology developers in academic settings and industry, patients, clinicians, regional health authority and hos...
Who is eligible under the newly expanded process to submit patient input to the CADTH pan-Canadian Oncology Drug Review (pCODR) program as an individual patient or caregiver? pCODR will accept patient input from individual patients and caregivers when there is no patient advocacy group representing patients with the particular tumour for w...